TY  - BOOK
AU  - Ting,Naitee
AU  - Chen,Ding-Geng
AU  - Ho,Shuyen
AU  - Cappelleri,Joseph C.
ED  - SpringerLink (Online service)
TI  - Phase II Clinical Development of New Drugs
T2  - ICSA Book Series in Statistics,
SN  - 9789811041945
AV  - QA276-280 
U1  - 519.5 23
PY  - 2017///
CY  - Singapore
PB  - Springer Singapore, Imprint: Springer
KW  - Statistics 
KW  - Pharmaceutical technology
KW  - Management
KW  - Statistics for Life Sciences, Medicine, Health Sciences
KW  - Pharmaceutical Sciences/Technology
N1  - Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials; Available to subscribing member institutions only. Доступно лише організаціям членам підписки
N2  - This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them
UR  - https://doi.org/10.1007/978-981-10-4194-5
ER  -